23.71
-0.37 (-1.54%)
| Previous Close | 24.08 |
| Open | 24.46 |
| Volume | 866,725 |
| Avg. Volume (3M) | 1,584,316 |
| Market Cap | 1,807,715,712 |
| Price / Earnings (TTM) | 74.09 |
| Price / Sales | 8.93 |
| Price / Book | 6.07 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Monte Rosa Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 37.00 (Piper Sandler, 56.05%) | Buy |
| Median | 34.00 (43.40%) | |
| Low | 30.00 (Wells Fargo, 26.53%) | Buy |
| Average | 33.67 (42.01%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 24.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 14 Jan 2026 | 37.00 (56.05%) | Buy | 24.06 |
| Guggenheim | 08 Jan 2026 | 34.00 (43.40%) | Buy | 25.31 |
| Wells Fargo | 08 Jan 2026 | 30.00 (26.53%) | Buy | 25.31 |
| 16 Dec 2025 | 22.00 (-7.21%) | Buy | 18.66 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |